Want to see IMNM full AI Analyst Report?
Top Page
Immunome
(NASDAQ:IMNM)
Select Model
Select Model
Rating:47Neutral
Price Target:
$21.00
▼(-28.52% Downside)
Action:Reiterated
Date:10/06/26
The score is primarily weighed down by weak financial performance (zero TTM revenue, large losses, and heavy cash burn) and bearish technicals (below key moving averages with negative MACD). The balance sheet strength and the BMS deal restructuring provide some offset, but valuation is not supportive given ongoing losses and no dividend.
Positive Factors
Low leverage and equity cushion
Minimal leverage reduces balance-sheet debt risk and preserves financial flexibility relative to a heavily indebted biotech. The substantial equity base provides a cushion for continued development spending and may improve the company’s ability to pursue strategic options over the next several quarters.
Negative Factors
Revenue has fallen to zero
The move to zero trailing-twelve-month revenue shows that Immunome currently lacks recurring commercial product sales or dependable operating revenue. This leaves near-term funding and progress dependent on pipeline events, partnerships, or financing rather than an established revenue base.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and equity cushion
Minimal leverage reduces balance-sheet debt risk and preserves financial flexibility relative to a heavily indebted biotech. The substantial equity base provides a cushion for continued development spending and may improve the company’s ability to pursue strategic options over the next several quarters.
Read all positive factors
Immunome (IMNM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.31B
Dividend YieldN/A
Average Volume (3M)1.26M
Price to Earnings (P/E)―
Beta (1Y)1.56
Revenue Growth-100.00%
EPS Growth18.12%
CountryUS
Employees247
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.54
Shares Outstanding118,003,110
10 Day Avg. Volume1,468,064
30 Day Avg. Volume1,262,727
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.96
Price to Sales (P/S)270.32
P/FCF Ratio-9.35
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-37.69
Enterprise Value/Ebitda-7.50
Forecast
1Y Price Target
$35.36Price Target Upside20.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.31
Revenue Forecast (FY)$363.64K
Immunome Business Overview & Revenue Model
Company Description
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comp...
How the Company Makes Money
Immunome’s revenue model is primarily based on (1) collaboration and licensing economics and (2) other strategic/transactional payments, rather than recurring product sales (commercial product revenue: null). Key ways the company makes money inclu...
Immunome Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 6.94M | 9.04M | 14.02M | 0.00 | 0.00 |
| Gross Profit | -49.95M | 3.99M | 9.04M | 14.02M | 0.00 | 0.00 |
| EBITDA | -250.90M | -209.44M | -151.35M | -28.00M | -36.26M | -23.95M |
| Net Income | -254.32M | -212.39M | -292.96M | -106.81M | -36.90M | -24.71M |
Balance Sheet | ||||||
| Total Assets | 565.38M | 683.19M | 240.24M | 148.54M | 24.05M | 57.92M |
| Cash, Cash Equivalents and Short-Term Investments | 520.00M | 653.48M | 217.30M | 138.14M | 20.32M | 49.23M |
| Total Debt | 4.59M | 3.85M | 4.83M | 1.65M | 291.00K | 317.00K |
| Total Liabilities | 40.30M | 48.84M | 59.08M | 28.66M | 7.39M | 9.74M |
| Stockholders Equity | 525.08M | 634.34M | 181.16M | 119.88M | 16.65M | 48.19M |
Cash Flow | ||||||
| Free Cash Flow | -219.09M | -200.60M | -164.30M | -8.40M | -28.94M | -18.30M |
| Operating Cash Flow | -208.79M | -190.92M | -110.79M | -7.57M | -28.69M | -18.23M |
| Investing Cash Flow | -196.48M | 60.80M | -85.06M | -30.48M | -248.00K | -79.00K |
| Financing Cash Flow | 479.11M | 640.36M | 240.53M | 116.41M | 32.00K | 27.77M |
Immunome Technical Analysis
Negative
29.38
Price Trends
24.94
Negative
23.06
Negative
22.72
Negative
Market Momentum
-1.62
Positive
30.18
Neutral
16.64
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMNM, the sentiment is Negative. The current price of 29.38 is above the 20-day moving average (MA) of 22.20, above the 50-day MA of 24.94, and above the 200-day MA of 22.72, indicating a bearish trend. The MACD of -1.62 indicates Positive momentum. The RSI at 30.18 is Neutral, neither overbought nor oversold. The STOCH value of 16.64 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMNM.
Immunome Risk Analysis
Immunome disclosed 75 risk factors in its most recent earnings report. Immunome reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Immunome Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $1.37B | 6.81 | 2515.23% | ― | 92.92% | ― | |
57 Neutral | $1.83B | -11.35 | -28.66% | ― | -28.56% | 10.25% | |
54 Neutral | $1.84B | -12.77 | -72.07% | ― | -69.78% | -106.07% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $2.35B | -6.86 | -52.36% | ― | -97.27% | -44.90% | |
48 Neutral | $999.43M | -4.61 | -52.89% | ― | ― | 3.56% | |
47 Neutral | $2.31B | -7.70 | -50.56% | ― | -100.00% | 18.12% |
* Healthcare Sector Average
IMNM
Immunome
19.55
5.30
37.19%
CLDX
Celldex
29.89
2.76
10.17%
XNCR
Xencor
24.63
10.67
76.43%
ANAB
AnaptysBio
45.95
24.31
112.38%
ZYME
Zymeworks
25.79
7.68
42.41%
CGEM
Cullinan Management
15.53
7.70
98.34%
Immunome Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Immunome Restructures BMS Deal, Gains Key Patent Rights
Positive
Oct 5, 2026
On October 2, 2026, Immunome, Inc. amended its long-standing license agreement with Bristol-Myers Squibb, eliminating all future milestone, royalty and other payment obligations to BMS tied to varegacestat and AL101. In exchange, Immunome secured ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.